Jane Street
XFOR icon

Jane Street’s X4 Pharmaceuticals XFOR Stock Holding History

Jane Street’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$153K Sell
37,143
-54,270
-59% -$203K ﹤0.01% 10372
2025
Q4 		$366K Buy
+91,413
New +$332K ﹤0.01% 8391
2025
Q3 		– Sell
-97,344
Closed -$185K – 11907
2025
Q2 		$185K Buy
+97,344
New +$398K ﹤0.01% 8611
2025
Q1 		– Sell
-19,449
Closed -$268K – 10791
2024
Q4 		$428K Buy
19,449
+11,167
+135% +$178K ﹤0.01% 7113
2024
Q3 		$166K Buy
8,282
+4,210
+103% +$87.9K ﹤0.01% 8762
2024
Q2 		$70.8K Buy
4,072
+1,490
+58% +$48.7K ﹤0.01% 8842
2024
Q1 		$108K Sell
2,582
-1,727
-40% -$48K ﹤0.01% 8504
2023
Q4 		$108K Buy
4,309
+3,863
+866% +$93.9K ﹤0.01% 8545
2023
Q3 		$14.6K Sell
446
-11,523
-96% -$503K ﹤0.01% 8343
2023
Q2 		$697K Buy
11,969
+11,250
+1,565% +$578K ﹤0.01% 5798
2023
Q1 		$18.8K Buy
+719
New +$21.1K ﹤0.01% 8660
2022
Q2 		– Sell
-1,228
Closed -$64K – 11064
2022
Q1 		$64K Buy
+1,228
New +$70.4K ﹤0.01% 9616
2021
Q3 		– Sell
-2,389
Closed -$466K – 10852
2021
Q2 		$466K Buy
+2,389
New +$601K ﹤0.01% 7379

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Jane Street's XFOR Position: Q1 2026 in Review

Jane Street reduced its X4 Pharmaceuticals (XFOR) stake by 59% in Q1 2026, selling an estimated $203K and leaving 37,143 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #10372.

Jane Street first reported a position in XFOR in Q2 2021 and has held it in 13 quarters since. The position peaked at $697K in Q2 2023. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Jane Street held 37,143 shares of X4 Pharmaceuticals worth $153K as of Q1 2026.
  • Jane Street sold 54,270 X4 Pharmaceuticals shares in Q1 2026, an estimated $203K.
  • X4 Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10372 holding.
  • Jane Street first reported a position in X4 Pharmaceuticals in Q2 2021 and has held it in 13 quarters since.
  • Jane Street's X4 Pharmaceuticals position peaked at $697K in Q2 2023.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.